On the other hand, IL-12/IL-23 inhibitors are effective against psoriasis (PsO) and psoriatic arthritis (PsA), predominantly on peripheral synovitis and enthesitis in axSpA (1), while the efficacy on axial manifestations remains inconclusive. This evidence concerns the gene IL23A and enthesitis.